CLEARSIDE BIOMEDICAL, INC. (NASDAQ:CLSD) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 22, 2017, Clearside Biomedical, Inc. (the Company) held
its 2017 annual meeting of stockholders (the Annual Meeting). The
stockholders considered two proposals, each of which is described
in more detail in the Companys definitive proxy statement filed
with the Securities and Exchange Commission on April 28, 2017. Of
the 25,300,016 shares outstanding as of the record date,
21,386,173 shares, or 84.5%, were present or represented by proxy
at the Annual Meeting. Set forth below are the results of the
matters submitted for a vote of stockholders at the Annual
Meeting.
Proposal No. 1: Election of two nominees to serve as directors
until the 2020 annual meeting of stockholders and until their
respective successors are elected and qualified. The votes were
cast as follows:
|
Name |
Votes For |
Votes Withheld |
|
Daniel H. White |
14,822,597 |
713,762 |
|
Clay B. Thorp |
14,728,349 |
808,010 |
Broker Non-Votes: 5,849,814.
All nominees were elected.
Proposal No. 2: Ratification of the appointment of Ernst Young
LLP as independent registered public accounting firm for the
fiscal year ending December 31, 2017. The votes were cast as
follows:
|
Votes For |
Votes Against |
Abstained |
|
|
Ratification of appointment of Ernst Young LLP |
21,381,922 |
4,246 |
About CLEARSIDE BIOMEDICAL, INC. (NASDAQ:CLSD)
Clearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment. With its microinjector, drugs are injected into and spread within and through the suprachoroidal space, (SCS), which is the space located between the choroid and the outer protective layer of the eye known as the sclera. With the suprachoroidal injection, its product candidates are more directly administered to the retina and choroid as compared to other ocular drug administration techniques, such as injections of drug into the vitreous, a jelly-like substance that occupies the central portion of the eye.
